Accueil
| Titre : | Drug and Alcohol Dependence, Vol.70, n°2 Suppl.. Buprenorphine and buprenorphine/naloxone : A guide for clinicians - May 2003 |
| Type de document : | Bulletin |
| Paru le : | 21/05/2003 |
Dépouillements
Ajouter le résultat dans votre panierArticle : Périodique
ENGLISH :
The practice of prescribing opioid drugs for opioid dependent patients in the U.S. has been subjected to special government scrutiny for almost 100 years. From 1920 until 1964, doctors who used opioids to treat addicts risked federal[...]
Article : Périodique
ENGLISH :
This paper will review clinical pharmacology studies on buprenorphine, a mixed opioid agonist-antagonist currently approved as a treatment for opioid dependence. The focus is on studies characterizing buprenorphine's pharmacodynamic [...]
Article : Périodique
Although only a partial u-opiate agonist, buprenorphine can be abused and diverted from medical therapy to the illicit drug market. A combination of buprenorphine and naloxone for sublingual administration may discourage diversion and abuse by p[...]
Article : Périodique
ENGLISH :
The sublingual combination tablet formulation of buprenorphine and naloxone at a fixed dose ratio of 4:1 has been shown to be as effective as the tablet formulation containing only buprenorphine in treating opiate addiction. The addi[...]
Article : Périodique
ENGLISH :
The early clinical studies suggested that, in clinical settings, buprenorphine was a safe and efficacious opiate dependence pharmacotherapy. Formal approval for general clinical use, however, required that systematic data be gathered[...]
Article : Périodique
The unique pharmacology of buprenorphine at the mu-opioid receptor (i.e. high affinity, low intrinsic activity and slow dissociation) results in buprenorphine having: (1) a good safety profile, (2) low physical dependence, and (3) flexibility in[...]
Article : Périodique
ENGLISH :
It is estimated that 55-94% of infants born to opioid-dependent mothers in US will show signs of opioid withdrawal. Buprenorphine has been reported to produce little or no autonomic signs or symptoms of opioid withdrawal following ab[...]
Article : Périodique
Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting
FRANÇAIS :
Le fait que la FDA a approuvé la buprenorphine et l'association buprénorphine/naloxone dans le traitement de l'addiction et permis sa dispensation en pratique médicale ouvre une voie pour l'extension de l'accès au traitement de subst[...]
Article : Périodique
Opiate dependence remains a fundamental challenge confronting health delivery systems and is often characterized as a social and moral issue. The impact of this disorder on healthcare policy is changing with the increased incidence of HIV, hepat[...]
